{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:06:29Z","timestamp":1795208789899,"version":"4.10.3"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00208037"],"award-info":[{"award-number":["RS-2023-00208037"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1A5A2020732"],"award-info":[{"award-number":["2018R1A5A2020732"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2025IL0005"],"award-info":[{"award-number":["2025IL0005"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2025IF0030"],"award-info":[{"award-number":["2025IF0030"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Chimeric antigen receptors (CARs) are synthetic receptors that reprogram the target specificity and functions of CAR-expressing effector cells. The design of CAR constructs typically includes an extracellular antigen-binding moiety, hinge (H), transmembrane (TM), and intracellular signaling domains. Conventional CAR constructs are primarily designed for T cells but have been directly adopted for other effector cells, including natural killer (NK) cells, without tailored optimization. Given the benefits of CAR-NK cells over CAR-T cells in terms of safety, off-the-shelf utility, and antigen escape, there is an increasing emphasis on tailoring them to NK cell activation mechanisms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We first have taken a stepwise approach to modifying CAR components such as the combination and order of the H, TM, and signaling domains to achieve such tailoring in NK cells. Functionality of NK-tailored CARs were evaluated in vitro and in vivo in a model of CD19-expressing lymphoma, along with their expression and signaling properties in NK cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We found that NK-CAR driven by the synergistic combination of NK receptors NKG2D and 2B4 rather than DNAM-1 and 2B4 induces potent activation in NK cells. Further, more effective CAR-mediated cytotoxicity was observed following the sequential combination of DAP10, but not NKG2D TM, with 2B4 signaling domain despite the capacity of NKG2D TM to recruit endogenous DAP10 for signaling. Accordingly, an NK-CAR incorporating DAP10, 2B4, and CD3\u03b6 signaling domains coupled to CD8\u03b1 H and CD28 TM domains was identified as the most promising candidate to improve CAR-mediated cytotoxicity. This NK-tailored CAR provided more potent antitumor activity than a conventional T-CAR when delivered to NK cells both in vitro and in vivo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Hence, NK receptor-based domains hold great promise for the future of NK-CAR design with potentially significant therapeutic benefits.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13046-025-03351-5","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T02:36:27Z","timestamp":1741228587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["A chimeric antigen receptor tailored to integrate complementary activation signals potentiates the antitumor activity of NK cells"],"prefix":"10.1186","volume":"44","author":[{"given":"Eunbi","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunbi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Hyeon","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5729-6581","authenticated-orcid":false,"given":"Hun Sik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"24","key":"3351_CR1","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3351_CR2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3351_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","volume":"21","author":"M Sadelain","year":"2009","unstructured":"Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21(2):215\u201323.","journal-title":"Curr Opin Immunol"},{"issue":"9","key":"3351_CR4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med. 2019;25(9):1341\u201355.","journal-title":"Nat Med"},{"issue":"3","key":"3351_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3351_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145\u201361.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3351_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"26","key":"3351_CR8","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"3351_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"issue":"14","key":"3351_CR10","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331\u201342.","journal-title":"N Engl J Med"},{"issue":"26","key":"3351_CR11","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Chimeric antigen receptor T cells in refractory B-Cell lymphomas. N Engl J Med. 2017;377(26):2545\u201354.","journal-title":"N Engl J Med"},{"issue":"10","key":"3351_CR12","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell Therapy. Cancer Discov. 2018;8(10):1219\u201326.","journal-title":"Cancer Discov"},{"key":"3351_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0065-2776(08)60262-X","volume":"27","author":"RM Zinkernagel","year":"1979","unstructured":"Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol. 1979;27:51\u2013177.","journal-title":"Adv Immunol"},{"issue":"3","key":"3351_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185\u201399.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"3351_CR15","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1111\/trf.14569","volume":"58","author":"F Ceppi","year":"2018","unstructured":"Ceppi F, Rivers J, Annesley C, Pinto N, Park JR, Lindgren C, et al. Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma. Transfusion. 2018;58(6):1414\u201320.","journal-title":"Transfusion"},{"key":"3351_CR16","doi-asserted-by":"crossref","unstructured":"Lonez C, Breman E. Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met? Cells. 2024;13(2):146.","DOI":"10.3390\/cells13020146"},{"key":"3351_CR17","doi-asserted-by":"publisher","first-page":"673276","DOI":"10.3389\/fonc.2021.673276","volume":"11","author":"F Marofi","year":"2021","unstructured":"Marofi F, Al-Awad AS, Sulaiman Rahman H, Markov A, Abdelbasset WK, Ivanovna Enina Y, et al. CAR-NK cell: a new paradigm in tumor immunotherapy. Front Oncol. 2021;11:673276.","journal-title":"Front Oncol"},{"issue":"1","key":"3351_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14(1):73.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3351_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","volume":"14","author":"S Liu","year":"2021","unstructured":"Liu S, Galat V, Galat Y, Lee YKA, Wainwright D, Wu J. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021;14(1):7.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3351_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc.2015.5","volume":"16","author":"MG Morvan","year":"2016","unstructured":"Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16(1):7\u201319.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"3351_CR21","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ni.3518","volume":"17","author":"C Guillerey","year":"2016","unstructured":"Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol. 2016;17(9):1025\u201336.","journal-title":"Nat Immunol"},{"issue":"2","key":"3351_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ccell.2017.06.009","volume":"32","author":"A Lopez-Soto","year":"2017","unstructured":"Lopez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of Metastasis by NK Cells. Cancer Cell. 2017;32(2):135\u201354.","journal-title":"Cancer Cell"},{"key":"3351_CR23","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.3389\/fimmu.2019.02357","volume":"10","author":"M Carlsten","year":"2019","unstructured":"Carlsten M, Jaras M. Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells. Front Immunol. 2019;10:2357.","journal-title":"Front Immunol"},{"issue":"1","key":"3351_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13287-021-02277-x","volume":"12","author":"MG Lamb","year":"2021","unstructured":"Lamb MG, Rangarajan HG, Tullius BP, Lee DA. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. Stem Cell Res Ther. 2021;12(1):211.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"3351_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200\u201318.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"3351_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","volume":"21","author":"A Page","year":"2024","unstructured":"Page A, Chuvin N, Valladeau-Guilemond J, Depil S. Development of NK cell-based cancer immunotherapies through receptor engineering. Cell Mol Immunol. 2024;21(4):315\u201331.","journal-title":"Cell Mol Immunol"},{"key":"3351_CR27","doi-asserted-by":"publisher","first-page":"822298","DOI":"10.3389\/fimmu.2022.822298","volume":"13","author":"KE Ruppel","year":"2022","unstructured":"Ruppel KE, Fricke S, Kohl U, Schmiedel D. Taking lessons from CAR-T cells and going beyond: tailoring design and signaling for CAR-NK cells in cancer therapy. Front Immunol. 2022;13:822298.","journal-title":"Front Immunol"},{"key":"3351_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","volume":"23","author":"LL Lanier","year":"2005","unstructured":"Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225\u201374.","journal-title":"Annu Rev Immunol"},{"key":"3351_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","volume":"31","author":"EO Long","year":"2013","unstructured":"Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013;31:227\u201358.","journal-title":"Annu Rev Immunol"},{"issue":"5701","key":"3351_CR30","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1126\/science.1103478","volume":"306","author":"E Vivier","year":"2004","unstructured":"Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science. 2004;306(5701):1517\u20139.","journal-title":"Science"},{"issue":"1","key":"3351_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2005-04-1351","volume":"107","author":"YT Bryceson","year":"2006","unstructured":"Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107(1):159\u201366.","journal-title":"Blood"},{"issue":"2","key":"3351_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.immuni.2010.02.004","volume":"32","author":"HS Kim","year":"2010","unstructured":"Kim HS, Das A, Gross CC, Bryceson YT, Long EO. Synergistic signals for natural cytotoxicity are required to overcome inhibition by c-Cbl ubiquitin ligase. Immunity. 2010;32(2):175\u201386.","journal-title":"Immunity"},{"issue":"5","key":"3351_CR33","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/ni1325","volume":"7","author":"JL Upshaw","year":"2006","unstructured":"Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol. 2006;7(5):524\u201332.","journal-title":"Nat Immunol"},{"issue":"3","key":"3351_CR34","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.coi.2011.01.005","volume":"23","author":"N Engels","year":"2011","unstructured":"Engels N, Wienands J. The signaling tool box for tyrosine-based costimulation of lymphocytes. Curr Opin Immunol. 2011;23(3):324\u20139.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"3351_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nri1761","volume":"6","author":"A Veillette","year":"2006","unstructured":"Veillette A. Immune regulation by SLAM family receptors and SAP-related adaptors. Nat Rev Immunol. 2006;6(1):56\u201366.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"3351_CR36","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1084\/jem.20150792","volume":"212","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, Wu N, Lu Y, Davidson D, Colonna M, Veillette A. DNAM-1 controls NK cell activation via an ITT-like motif. J Exp Med. 2015;212(12):2165\u201382.","journal-title":"J Exp Med"},{"issue":"1","key":"3351_CR37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-023-01455-z","volume":"16","author":"F Meng","year":"2023","unstructured":"Meng F, Zhang S, Xie J, Zhou Y, Wu Q, Lu B, et al. Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells. J Hematol Oncol. 2023;16(1):62.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"3351_CR38","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/cac2.12321","volume":"42","author":"L Wu","year":"2022","unstructured":"Wu L, Liu F, Yin L, Wang F, Shi H, Zhao Q, et al. The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death. Cancer Commun (Lond). 2022;42(8):768\u201383.","journal-title":"Cancer Commun (Lond)"},{"key":"3351_CR39","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.2147\/CMAR.S253565","volume":"12","author":"Y Huang","year":"2020","unstructured":"Huang Y, Zeng J, Liu T, Xu Q, Song X, Zeng J. DNAM1 and 2B4 costimulatory domains enhance the cytotoxicity of anti-GPC3 chimeric antigen receptor-modified natural killer cells against hepatocellular cancer cells in vitro. Cancer Manag Res. 2020;12:3247\u201355.","journal-title":"Cancer Manag Res"},{"key":"3351_CR40","doi-asserted-by":"publisher","first-page":"886319","DOI":"10.3389\/fimmu.2022.886319","volume":"13","author":"C Focaccetti","year":"2022","unstructured":"Focaccetti C, Benvenuto M, Pighi C, Vitelli A, Napolitano F, Cotugno N, et al. DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells in vitro: a proof-of-concept study. Front Immunol. 2022;13:886319.","journal-title":"Front Immunol"},{"issue":"1","key":"3351_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cei.13478","volume":"202","author":"J Obajdin","year":"2020","unstructured":"Obajdin J, Davies DM, Maher J. Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer. Clin Exp Immunol. 2020;202(1):11\u201327.","journal-title":"Clin Exp Immunol"},{"key":"3351_CR42","doi-asserted-by":"publisher","first-page":"11686","DOI":"10.1038\/ncomms11686","volume":"7","author":"HJ Kwon","year":"2016","unstructured":"Kwon HJ, Choi GE, Ryu S, Kwon SJ, Kim SC, Booth C, et al. Stepwise phosphorylation of p65 promotes NF-kappaB activation and NK cell responses during target cell recognition. Nat Commun. 2016;7:11686.","journal-title":"Nat Commun"},{"issue":"9","key":"3351_CR43","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cellsig.2015.05.012","volume":"27","author":"HJ Kwon","year":"2015","unstructured":"Kwon HJ, Kwon SJ, Lee H, Park HR, Choi GE, Kang SW, et al. NK cell function triggered by multiple activating receptors is negatively regulated by glycogen synthase kinase-3beta. Cell Signal. 2015;27(9):1731\u201341.","journal-title":"Cell Signal"},{"key":"3351_CR44","doi-asserted-by":"crossref","unstructured":"Hyun YM, Seo SU, Choi WS, Kwon HJ, Kim DY, Jeong S, et al. Endogenous DEL-1 restrains melanoma lung metastasis by limiting myeloid cell-associated lung inflammation. Sci Adv. 2020;6(45):eabc4882.","DOI":"10.1126\/sciadv.abc4882"},{"issue":"29","key":"3351_CR45","doi-asserted-by":"publisher","first-page":"e2400920","DOI":"10.1002\/advs.202400920","volume":"11","author":"WS Choi","year":"2024","unstructured":"Choi WS, Kwon HJ, Yi E, Lee H, Kim JM, Park HJ, et al. HPK1 dysregulation-associated NK cell dysfunction and defective expansion promotes metastatic melanoma progression. Adv Sci (Weinh). 2024;11(29):e2400920.","journal-title":"Adv Sci (Weinh)"},{"issue":"21","key":"3351_CR46","doi-asserted-by":"publisher","first-page":"7641","DOI":"10.1073\/pnas.0502439102","volume":"102","author":"D Garrity","year":"2005","unstructured":"Garrity D, Call ME, Feng J, Wucherpfennig KW. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci U S A. 2005;102(21):7641\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3351_CR47","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","volume":"12","author":"S Guedan","year":"2019","unstructured":"Guedan S, Calderon H, Posey AD Jr, Maus MV. Engineering and design of chimeric antigen receptors. Mol Ther Methods Clin Dev. 2019;12:145\u201356.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"11","key":"3351_CR48","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1182\/blood-2009-08-238469","volume":"115","author":"C Fauriat","year":"2010","unstructured":"Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood. 2010;115(11):2167\u201376.","journal-title":"Blood"},{"issue":"10","key":"3351_CR49","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederstadt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22(10):557\u201375.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3351_CR50","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.7150\/ijbs.88539","volume":"20","author":"J Li","year":"2024","unstructured":"Li J, Hu H, Lian H, Yang S, Liu M, He J, et al. NK-92MI cells engineered with anti-claudin-6 chimeric antigen receptors in immunotherapy for ovarian cancer. Int J Biol Sci. 2024;20(5):1578\u2013601.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"3351_CR51","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181-92 e5.","journal-title":"Cell Stem Cell."},{"issue":"1","key":"3351_CR52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.immuni.2009.05.009","volume":"31","author":"D Liu","year":"2009","unstructured":"Liu D, Bryceson YT, Meckel T, Vasiliver-Shamis G, Dustin ML, Long EO. Integrin-dependent organization and bidirectional vesicular traffic at cytotoxic immune synapses. Immunity. 2009;31(1):99\u2013109.","journal-title":"Immunity"},{"key":"3351_CR53","doi-asserted-by":"publisher","first-page":"102931","DOI":"10.1016\/j.ebiom.2020.102931","volume":"58","author":"J Jayaraman","year":"2020","unstructured":"Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, et al. CAR-T design: elements and their synergistic function. EBioMedicine. 2020;58:102931.","journal-title":"EBioMedicine"},{"issue":"1","key":"3351_CR54","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/imr.13313","volume":"323","author":"OA Aguilar","year":"2024","unstructured":"Aguilar OA, Fong LK, Lanier LL. ITAM-based receptors in natural killer cells. Immunol Rev. 2024;323(1):40\u201353.","journal-title":"Immunol Rev"},{"issue":"22","key":"3351_CR55","doi-asserted-by":"publisher","first-page":"12445","DOI":"10.1073\/pnas.93.22.12445","volume":"93","author":"V Groh","year":"1996","unstructured":"Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A. 1996;93(22):12445\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3351_CR56","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1074-7613(01)00095-4","volume":"14","author":"D Cosman","year":"2001","unstructured":"Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14(2):123\u201333.","journal-title":"Immunity"},{"issue":"1","key":"3351_CR57","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1286-4579(02)00057-6","volume":"5","author":"C Watzl","year":"2003","unstructured":"Watzl C. The NKG2D receptor and its ligands-recognition beyond the \u201cmissing self\u201d? Microbes Infect. 2003;5(1):31\u20137.","journal-title":"Microbes Infect"},{"issue":"10","key":"3351_CR58","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1158\/2159-8290.CD-24-0096","volume":"14","author":"S Acharya","year":"2024","unstructured":"Acharya S, Basar R, Daher M, Rafei H, Li P, Uprety N, et al. CD28 costimulation augments CAR signaling in NK cells via the LCK\/CD3zeta\/ZAP70 signaling axis. Cancer Discov. 2024;14(10):1879\u2013900.","journal-title":"Cancer Discov"},{"issue":"1","key":"3351_CR59","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-019-0732-7","volume":"12","author":"Y Xu","year":"2019","unstructured":"Xu Y, Liu Q, Zhong M, Wang Z, Chen Z, Zhang Y, et al. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies. J Hematol Oncol. 2019;12(1):49.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"3351_CR60","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.4049\/jimmunol.1400330","volume":"194","author":"K Topfer","year":"2015","unstructured":"Topfer K, Cartellieri M, Michen S, Wiedemuth R, Muller N, Lindemann D, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol. 2015;194(7):3201\u201312.","journal-title":"J Immunol"},{"issue":"1","key":"3351_CR61","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ymthe.2020.08.016","volume":"29","author":"YY Ng","year":"2021","unstructured":"Ng YY, Tay JCK, Li Z, Wang J, Zhu J, Wang S. T cells expressing NKG2D CAR with a DAP12 signaling domain stimulate lower cytokine production while effective in tumor eradication. Mol Ther. 2021;29(1):75\u201385.","journal-title":"Mol Ther"},{"key":"3351_CR62","doi-asserted-by":"crossref","unstructured":"Salter AI, Ivey RG, Kennedy JJ, Voillet V, Rajan A, Alderman EJ, et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal. 2018;11(544):eaat6753.","DOI":"10.1126\/scisignal.aat6753"},{"issue":"2","key":"3351_CR63","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520\u201331.","journal-title":"Leukemia"},{"issue":"6","key":"3351_CR64","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545\u201353.","journal-title":"N Engl J Med"},{"issue":"11","key":"3351_CR65","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","volume":"31","author":"L Tang","year":"2023","unstructured":"Tang L, Pan S, Wei X, Xu X, Wei Q. Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development. Mol Ther. 2023;31(11):3146\u201362.","journal-title":"Mol Ther"},{"issue":"48","key":"3351_CR66","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A. 2016;113(48):E7788\u201397.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"3351_CR67","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051\u20137.","journal-title":"Blood"},{"issue":"5","key":"3351_CR68","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.2020007748","volume":"137","author":"M Daher","year":"2021","unstructured":"Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021;137(5):624\u201336.","journal-title":"Blood"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03351-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03351-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03351-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T14:31:27Z","timestamp":1741271487000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03351-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3351"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03351-5","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All mouse experimental protocols were approved by the Institutional Animal Care and Use Committee of the Asan Institute for Life Sciences (Approval No. 2021\u201313-122).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}